J Cancer 2019; 10(23):5628-5637. doi:10.7150/jca.32690

Research Paper

Disease-specific haptoglobin-β chain N-glycosylation as biomarker to differentiate non-small cell lung cancer from benign lung diseases

Tianjing Chen1, Chengyan He2, Mo Zhang1, Xiaoou Li3, Xiaofeng Liu3, Yujie Liu1, Dan Zhang1, Zhili Li1,✉

1. Department of Biophysics and Structural Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & School of Basic Medicine, Peking Union Medical College, Beijing, PR China
2. Clinical Lab Diagnosis, China-Japan Union Hospital, Jilin University, Changchun, PR China
3. Department of Laboratory, Tumor Hospital of Jilin Province, Changchun, PR China

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Chen T, He C, Zhang M, Li X, Liu X, Liu Y, Zhang D, Li Z. Disease-specific haptoglobin-β chain N-glycosylation as biomarker to differentiate non-small cell lung cancer from benign lung diseases. J Cancer 2019; 10(23):5628-5637. doi:10.7150/jca.32690. Available from http://www.jcancer.org/v10p5628.htm

File import instruction

Abstract

Background: The association of pathological states with N-glycosylation of haptoglobin-β has attracted increasing attention.

Materials & Methods: In the present study, disease-specific haptoglobin-β (DSHp-β) was separated from serum immunoinflammation-related protein complexes (IIRPCs) of 600 participants including 300 patients with benign lung diseases (BLDs) and 300 patients with non-small cell lung cancer (NSCLC). The enriched glycopeptides of the tryptic digests of the DSHp-β were analyzed using matrix assisted laser desorption/ionization-Fourier transform ion cyclotron resonance mass spectrometry (MALDI-FTICR MS).

Results: 20 of glycopeptides were detected for each sample. The statistical analysis has indicated that significant changes in the sialylation of DSHp-β between BLDs and NSCLC patients were observed. The age- and sex-matched participants were randomly clarified into the training set and the validation set. Receiver operating characteristic (ROC) analysis has revealed that the level ratio of glycopeptides (G2G3/G2G3S4) at the sites of Asn207/211 has potential capability to distinguish BLDs from NSCLC, with the sensitivity of 74.4%, the specificity of 82.8%, and the area under curve (AUC) of 0.805.

Conclusion: The glycosylation of DSHp-β can distinguish NSCLC from BLDs with high diagnostic accuracy compared with current clinical available serum markers.

Keywords: disease-specific haptoglobin β chain, glycosylation, lung diseases, pathological state, matrix assisted laser desorption/ionization-mass spectrometry.